Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Tesla, Inc. (TSLA) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade

Tesla, Inc.Trade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Tesla, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Tesla, Inc. trades at $334.05 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 138.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.

	BIO	TSLA
Market Cap	$9.43B	$1.31T
Sector	Health	Consumer Cyclical
52-Week High	$356.25	$489.88
52-Week Low	$241.71	$298.16
Enterprise Value	$9.18B	$1.29T

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

No Aura AI signal available yet.

Tesla, Inc.

Tesla (TSLA) trades at $330.87, up 0.7% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key resistance at $333 and support at $327, while fundamentals reveal high valuation multiples (P/E 306.37) and declining profit margins (net margin 3.67% in 2025). Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch, balancing near-term delivery misses with long-term innovation bets.

Tesla's outlook hinges on executing its pivot to AI and autonomy amid slowing auto growth. Investment opportunities lie in market leadership in self-driving technology and energy expansion, but risks include intense EV competition, execution challenges, and rich valuations that demand flawless growth. Wall Street remains divided, with a $393.87 consensus target suggesting upside if catalysts materialize.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BIO

View details →

TSLA

Humanoid robot boom drives huge memory demand, spotlighting Micron as key supplier amid tight DRAM supply.24/7 Wall Street · 21 hours agoBullish Unitree's $900M IPO oversubscribed 8,000x signals booming investor interest in physical AI robotics.24/7 Wall Street · 22 hours agoBullish Nio shares drop 5% after BlackRock reduces stake despite strong delivery growth.24/7 Wall Street · 23 hours agoBearish View details →

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

About Tesla, Inc.

Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.